Takeda Pharmaceutical Co Ltd  

(Public, TYO:4502)   Watch this stock  
Find more results for 4502
4,827.00
+20.50 (0.43%)
Sep 16 - Close
TYO data delayed by 20 mins - Disclaimer
Currency in JPY
Range 4,787.00 - 4,827.50
52 week 4,396.00 - 5,170.00
Open 4,806.50
Vol / Avg. 1.86M/1.88M
Mkt cap 3.81T
P/E     -
Div/yield 90.00/3.73
EPS     -
Shares 786.02M
Beta     -
Inst. own     -
Oct 30, 2014
Q2 2015 Takeda Pharmaceutical Co Ltd Earnings Release - 3:00PM GMT+9 - Add to calendar
Sep 8, 2014
Takeda Pharmaceutical Co Ltd at Bank of America Merrill Lynch Japan Conference
Aug 1, 2014
Q1 2015 Takeda Pharmaceutical Co Ltd Earnings Call (Japanese)
Aug 1, 2014
Q1 2015 Takeda Pharmaceutical Co Ltd Earnings Call
Aug 1, 2014
Q1 2015 Takeda Pharmaceutical Co Ltd Earnings Release
Jun 27, 2014
Takeda Pharmaceutical Co Ltd Annual Shareholder Meeting (Japanese)
  

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin 9.47% 8.29%
Operating margin 15.49% 8.48%
EBITD margin - 20.99%
Return on average assets 3.52% 3.25%
Return on average equity 6.39% 5.79%
Employees 31,225 -
CDP Score - 79 C

Address

4-1-1, Dosho-machi, Chuo-ku
OSAKA-SHI, OSK 540-8645
Japan
+81-6-62042111 (Phone)
+81-6-62042880 (Fax)

Website links

External links

Description

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. In April 2014, the Company took over all business from Takeda Bio Development Center Limited. On September 3, 2014, it announced that it transferred Nippon Rinsho to Medical Tribune, Inc.

Officers and directors

Yasuchika Hasegawa Chairman of the Board, Chief Executive Officer, Representative Director
Age: 67
Christophe Weber President, Chief Operating Officer, Representative Director
Age: 47
Frank Morich Chief Commercial Officer, President of Subsidiary, Director
Age: 59
Tadataka Yamada Chief Medical and Scientific Officer, Director
Age: 68
Yasuhiko Yamanaka Managing Director
Age: 57
Masato Iwasaki Chief Director of Pharmaceutical Sales, Director
Age: 54
Shinji Honda Director of Business Planning, Director
Age: 55
Yorihiko Kojima Independent Director
Age: 72
Fumio Sudo Independent Director
Age: 72